Alx Oncology Holdings (ALXO) Receivables - Other (2019 - 2020)
Alx Oncology Holdings recorded quarterly Receivables - Other of $500000.0 in Q3 2020, little changed quarter-over-quarter from $500000.0 in Q2 2020.
Alx Oncology Holdings' Receivables - Other history runs 2 years deep, the most recent figure standing at $500000.0 for Q3 2020.
- In Q3 2020, Receivables - Other changed N/A year-over-year to $500000.0; the TTM figure through Sep 2020 stood at $500000.0 (changed N/A YoY), while the FY2019 annual figure was $536000.0, changed N/A from the prior year.
- Receivables - Other came in at $500000.0 for Q3 2020 at Alx Oncology Holdings, roughly flat from $500000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $536000.0 in Q4 2019 to a low of $500000.0 in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 500,000.00 |
| Sep 30, 2020 | 500,000.00 |
| Jun 30, 2020 | 500,000.00 |
| Jun 30, 2020 | 500,000.00 |
| Dec 31, 2019 | 536,000.00 |
| Dec 31, 2019 | 536,000.00 |